Biosimilars· June 24, 2026 · 17 min read
Darzalex Biosimilar Tracker: SC vs IV Formulations and the 2029 Market Entry Window
By Ran Chen#Biosimilars#Purple Book#Oncology
Topic
Buy and Bill
Buy-and-bill purchasing, provider-administered drug inventory risk, acquisition cost management, and specialty drug reimbursement.
Pricing & Access· June 24, 2026 · 26 min read
J&J Janssen Portfolio Dossier: Stelara Biosimilars and Oncology Assets
By Ran Chen#Purple Book#Orange Book#Biosimilars
Generics· June 22, 2026 · 19 min read
Generic Lanreotide Acetate: 505(b)(2) Approvals and Medical-Benefit Coding
By Ran Chen#Generics#FDA Approval#Orange Book
Biosimilars· June 22, 2026 · 20 min read
Poherdy (Pertuzumab-dpzb): FDA Approval and Payer Dynamics
By Ran Chen#Biosimilars#FDA Approval#Oncology
Manufacturing· June 14, 2026 · 11 min read
The oncology injectable shortage, in data: carboplatin and 18 chemo molecules
Pricing & Access· June 10, 2026 · 9 min read
CAR-T cell therapy access landscape: seven products in 2026
By Ran Chen#CAR-T#Oncology#Prior Authorization
Pricing & Access· June 10, 2026 · 10 min read
PD-1/PD-L1 checkpoint inhibitor access landscape in 2026
Approvals· June 7, 2026 · 8 min read
Imfinzi + BCG for NMIBC access guide: FDA approval, coding, and buy-and-bill
By Ran Chen#Oncology#PD-L1#Prior Authorization
Pricing & Access· June 6, 2026 · 10 min read
GLP-1 pharmacy vs medical benefit: routing, cost-sharing, and PA impact
By Ran Chen#GLP-1#Pharmacy Benefit#Medical Benefit
Pricing & Access· June 1, 2026 · 12 min read